CN1330371C - Recombinant human epidermal growth factor compound biological agent and its use - Google Patents
Recombinant human epidermal growth factor compound biological agent and its use Download PDFInfo
- Publication number
- CN1330371C CN1330371C CNB2004100006790A CN200410000679A CN1330371C CN 1330371 C CN1330371 C CN 1330371C CN B2004100006790 A CNB2004100006790 A CN B2004100006790A CN 200410000679 A CN200410000679 A CN 200410000679A CN 1330371 C CN1330371 C CN 1330371C
- Authority
- CN
- China
- Prior art keywords
- growth factor
- recombinant human
- epidermal growth
- human epidermal
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a compound biological preparation of a recombinant human epidermal growth factor and an application thereof. The compound biological preparation of a recombinant human epidermal growth factor comprises 2 to 10 ng/ml of recombinant human epidermal growth factor, 0% to 20% of fetal bovine serum, 2% to 10% of D-glucose, 0 to 10 mu g/ml of insulin, 0 to 5 mug/ml of hydrocortisone, 0 to 100 mu g/ml of ampicillin and 0 to 100 IU/ml of streptomycin sulfate, and multiplex distilled water is used as a solvent. The compound biological preparation of a recombinant human epidermal growth factor can be used for preparing a medicament for treating ulcer, fester, trauma and burn, and can also be used for producing anti-aging cosmetics and cosmetic products to keep the skin tender, reduce wrinkles, lighten or even eliminate color spots, and finally make the skin become glossy and elastic. The compound biological preparation of a recombinant human epidermal growth factor can also be used for preparing medicaments for treating traumatic eye diseases.
Description
Technical field
The present invention relates to a kind of biological preparation compositions and application thereof, particularly a kind of recombinant human epidermal growth factor composite biological agent and application thereof.
Background technology
Cohen and Levi Montalcin are in nineteen sixty, when mouse submandibular gland purifying nerve growth factor NGF, find, a kind of component that does not contain nerve growth factor is expelled to and can causes that eyelid early opens behind the newborn mice, the front tooth premature eruption, and hair growth suppresses and growth retardation.Cohen had reported this thermally-stabilised and sour stable albumen that has in 1962, can promote the growth of eyelid and front tooth.Histological research shows that eyelid is early opened because epidermal thickness and cornified characteristic increase cause.Outer this albumen of cultivating that studies confirm that of skin or epidermal tissue's block has direct effect to epidermal growth, therefore with its called after epidermal growth factor (epidermal growth factor, EGF).Research through many decades has been found that at present EGF is a protein families.The Brown research group shows that by random research (recombinant human epidermal growthfactor rhEGF) has the effect of tangible promotion wound healing to recombinant human epidermal growth factor.Thornton research group and other research groups discover that rhEGF can obviously promote rat II degree burn and shallow I degree wound healing (P＜0.01), also has the effect (P＜0.01) that promotes healing to skin donor site; And the facilitation of rhEGF mainly shows the later stage of wound healing.Early stage at wound healing, the slough on top layer tightly is overlying on wound surface, the rhEGF of topical application can't be penetrated and affact the remaining skin corium and the epithelial cell of the appendages of skin, can only treat the slough dissolving or come off, competence exertion appears behind the tangible skin island in wound surface, and it promotes growth effect.Studies show that between the clinical operating period, the liver of user, renal function and routine blood test etc. are all no abnormal at rhEGF, whole body and the quick reaction of local no mistake in treatment do not see that toxic and side effects takes place.Wound surface oozes out obviously and rapidly and reduces behind the local rhEGF of use, and this may promote epithelium with rhEGF, and factor such as regeneration is relevant rapidly.
EGF has its mitosis effect of promotion to multiple epithelial cell, also stimulate various Interstitial cell increments simultaneously, comprise endothelial cell, the intestines and stomach mucomembranous cell, vascular endothelial cell, vascular smooth muscle cell, fibroblast and chondrocyte, this just provides required basic substance for the growth of whole epidermis.Except short proliferation function, EGF can also promote the migration of some cell such as endothelial cell and vascular endothelial cell, and this reparation for wound is necessary.EGF can promote the reparation of cornea and skin wound epithelial cell and gastrointestinal mucosa ulcer wound surface, promotes epidermal cell proliferation, and can promote the deposition of collagen by stimulating the propagation of fibroblast and other cells.EGF over a period to come can non-standing ground improves the ability of fibroblasts proliferation.EGF has greatly facilitation to the growth of dermal fibroblast, has promoted the expression of cyclin CyclinD1 and CDk4 to strengthen, and cell cycle shortens, and multiplication capacity strengthens.Savage discovers that in 1972 EGF can promote corneal epithelium propagation, and a lot of scholars adopt animal corneal damage models such as corneal incision, cornea scratch, corneal epithelium excision and alkali burn also to confirm this point.In addition, find also that in the non-dystrophic disease of some corneal epitheliums the reparation that the EGF corneal is damaged has facilitation preferably.People such as Brown 1989 use EGF can significantly promote wound healing after 12 routine plastic surgery operations and burn patient are carried out skin transplantation.In addition, EGF also has obvious therapeutic action to gastric ulcer.
On parietal cell, the duodenal mucosa epithelial cell EGF receptor is arranged all.EGF is directly entered digestive tract or is brought into play biological effect to gastrointestinal mucosal in small intestinal by the brunner's gland direct secretion by saliva.EGF is a kind of important gastric mucosal protection factor, plays a role by combining with specific receptor EGFR on the gastrointestinal mucosa cell.The EGF level is one of important indicator of regenerated mucosa function maturity assessment in the ulcer healing quality in the gastric juice.Zoopery shows, mice intragastric infusion EGF can prevent the gastric ulcer that brought out by aspirin, and exogenous EGF can obviously suppress drug-induced gastric duodenal ulcer.
There are some researches show that peptic ulcer patient gastric juice EGF content is than the obvious reduction of normal person, the relation that the reduction of prompting EGF may be certain with having of gastric ulcer; Its gastric juice EGF content also obviously increases behind the gastric ulcer healing, shows that EGF may work in ulcer healing.At present, infer that according to experiment the possible mechanism of EGF participation peptic ulcer reparation is 1. to activate ODC Ornithine decarboxylase (ODC), it is synthetic to increase mucosa DNA; 2. gastric acid inhibitory secretion; 3. promote the synthetic and secretion of gastric mucosa mucous glycoprotein; 4. increase gastric mucosal blood flow.In clinical position, can predict the probability that ulcer takes place, in therapeutic process, can also this observe curative effect of medication simultaneously by dynamic monitoring gastric juice EGF content.
EGF is the factor of a kind of strong short cell division, differentiation, propagation, known it multiple tissue is had promote propagation and stimulate the synthetic effect of DNA, bring into play the activity of its promoting growth of cell by acting on specific receptor on the target cell membrane.In vitro study shows, EGF is chafe epithelial cell and fibroblasts proliferation, the formation of promotion new vessels and nucleic acid, protein and hydroxyproline synthetic initiatively.Animal experiment confirms, the recombinant human epidermal growth factor of denier (recombinant human epidermal growth factor, rhEGF) can play a role, (GF " the negative adjusting " reduces its effect that influences because of the EGF receptor number on the cell membrane is subjected to rhE on the contrary in the dosage increase.
There is data to show, EGF is the behavior of regulating cell by the reconstruction of extracellular matrix (ECM), or the reconstruction result of ECM promptly is the variation that has started cell phenotype by the release of EGF, and it is conjugated protein that ECM can separate EGF, i.e. the theory of relative growth factor active regulation and control.Along with the Celluar and Molecular Biology Progress in technique, the effect of cytokine in processes of wound repair paid attention to by people just gradually.
Insulin is secreted by beta Cell of islet, and proinsulin contains 86 aminoacid, and molecular weight is about 6,000, and insulin is made up of 51 aminoacid.Its structure of different animals is slightly variant, but does not influence its physiologically active.Insulin can promote cell to glucose, aminoacid and ionic picked-up, strengthens the phosphorylation of intracellular tyrosine and tryptophan, adjusts the activity of regulatory enzyme, stimulates or suppress the growth of transcribing and promoting cell of specific gene.Local use can promote wound healing, prevents the formation and the contracture of cicatrix.
Hydrocortisone is by the excretory a kind of glucocorticoid of adrenal cortex, regulates sugar, water, the salt metabolism of whole body, and using clinically can anti-inflammatory, antiallergic, antitoxin etc.It is synthetic that hydrocortisone can increase multiple anti-inflammatory molecular albumen, and as SLPT, the promotion inflammation alleviates or disappears.In addition, the hydrocortisone attack that can also alleviate the radical pair cell by the generation that suppresses free radical.Some scholars find that angiogenic edema and peripheral cell outer room matter oxygen radical removing degree are closely related, and hydrocortisone is an oxygen-derived free radicals non-enzyme scavenger, can directly remove OH
2With LOO
-Deng free radical.Hydrocortisone molecule hydrophobic group embeds in the film bimolecular hydrophobic region polyunsaturated fatty acid archway, makes the phospholipid bimolecular in conjunction with closely, and viscosity increases, and the blocking-up arachidonic acid discharges from cell membrane, thus the attack that alleviates oxygen-derived free radicals.Simultaneously, hydrocortisone not only suppresses the catalytic lipid peroxidation of ferrum in being rich in the phospholipid environment, also can suppress this reaction under no film composition participates in.Hydrocortisone is synthetic and discharge and increase through its receptor-mediated lipocortin and macrocortin of making, suppress the PDE activity, thereby blocking-up and inhibition prostaglandin cascade reaction reduce generation and the release of oxygen-derived free radicals and TXA2, leukotriene and PG, thereby reduce vascular permeability.Hydrocortisone can suppress macrophage nitric oxide synthetase activity, reduces the generation of macrophage-NO and oxygen-derived free radicals.In biological preparation, unite the quick reparation that use can not only promote the rotten position tissue, also protect cambium not to be subjected to the attack and the destruction of free radical with other compositions.
The mankind suffer from venous diseases such as varicosis, phlebitis, phlebothrombosis disease for a long time, and rheumatoid arthritis and diabetes cause body or local organization nutrition supply deficiency.The disease later stage will cause the legs and feet portion skin ulcer/long-term symptom that does not heal of festering to some extent, and the most prognosis of these patients is amputation.
Ulcer/fester is the septic result of body local inflammation dead skin.Varicosis/phlebitis ulcer/fester is what to be caused by a kind of chronic venous insufficiency.Varicose veins of the lower extremity is one of surgical common disease, and prevalence is very big in various countries' difference.The sickness rate of many American-European countries is up to 20%-40%, and Tropical Africa only is 01%.For example, in the crowd of Britain more than 50 years old, 50% people has slight varicosis symptom, wherein 10% hospitalization.There is 5% adult to suffer from chronic venous insufficiency to some extent; Women's prevalence is higher than the male.In China, investigation such as Zhang Peihua crowd's more than 15 years old sickness rate is to be 16.4% more than 8.6%, 45 years old, calculates existing about 80,000,000 to 100,000,000 examples of patient of China thus.Long-term vein hypertonicity or venous return are not smooth, will venous disease more often take place at femoral vein, saphena and the popliteal vein segment of shank.The varicosis patient of 10-25% suffers from arterial disease simultaneously; 12% diabetes and rheumatoid arthritis patient suffer from varicosis or phlebitis simultaneously.Up to the present, cause the cirsoid cause of disease not clear, may be relevant with factors such as family history, obesity, pregnancy and oral contraceptives, the occupation of standing for a long time simultaneously can increase the weight of cirsoid symptom.
At present the method for treatment venous ulcer has following several: 1. the patient wears two-stage or three grades (steps) have elastomeric socks, with the vein blood vessel below the extruding knee, in case downright badly further take place; 2. swathe 4 layers of binder at the affected part decussation, be respectively cotton yarn, crepe, Elset and Coban binder; These two kinds of treatments will continue about 12 weeks, and patient's symptom of nearly 45% can improve, and some patient's ulcer can also heal.3. excision: can excise shallow table vein for shallow varicosis or phlebitis patient, but cure rate only is 2%, and 100% recurrence after 4 years, the femoral vein that runs through shank all can be extracted out sometimes, but curative effect is all not obvious; Usually adopt excision ulcer, transplant graininess skin after removing slough for the patient of deep layer varicosis or inflammation, but healing is seldom arranged; 4. laser radiation is at least 3 months, can slow down venous pressure; 5. fly larvae therapy, fly larvae can effectively be removed the wound slough and help wound healing.
More than all Therapeutic Method be not loaded down with trivial details time-consuming, be exactly that curative effect is very little, therefore, have and fester or the patient of ulcer will stand for many years pain, exert heavy pressures on for their spirit, brought very big inconvenience to life.And, in a single day venous disease etc. cause festering of shank and foot after,, fester and on original downright bad basis, to continue to expand if the curative effect of above treatment is slow especially or invalid, the not smooth nutrition supply deficiency of venous return has more been aggravated the development of this symptom, finally causes patient's high amputation.
Radiation-induced skin ulcer is more common in the complication that radioactive accident and tumor radiotherapy etc. cause, its characteristics are that intractable shows effect repeatedly, long-term disunion, may develop into canceration at last.The molecular mechanism that development takes place this pathological changes it be unclear that, and more lacks effective treatment means.
The innovation and creation content
The purpose of this invention is to provide a kind of recombinant human epidermal growth factor composite biological agent.
Recombinant human epidermal growth factor composite biological agent provided by the present invention, comprise the 2-30ng/ml recombinant human epidermal growth factor, the 2-10%D-glucose, the 0-20% hyclone, 0-10 μ g/ml insulin, 0-5 μ g/ml hydrocortisone, 0-100 μ g/ml ampicillin and 0-100IU/ml streptomycin sulfate, solvent are multiple distilled water.
Amino acid whose content is with hyclone (FBS, interpolation cubage GIBCO).
Wherein, described recombinant human epidermal growth factor composite biological agent, be preferably and comprise the 5-10ng/ml recombinant human epidermal growth factor, the 5%D-glucose, the 0-20% hyclone, 0-8 μ g/ml insulin, 0-2 μ g/ml hydrocortisone, 0-100 μ g/ml ampicillin and 0-100IU/ml streptomycin sulfate.
When described recombinant human epidermal growth factor composite biological agent, by the 5ng/ml recombinant human epidermal growth factor, the 5%D-glucose, 5 μ g/ml insulins when 100IU/ml streptomycin sulfate and multiple distilled water are formed, can be used for treating ophthalmic diseases.
When described recombinant human epidermal growth factor composite biological agent, by 10% hyclone, the 5ng/ml recombinant human epidermal growth factor, the 5%D-glucose, 1 μ g/ml hydrocortisone, 5 μ g/ml or 8 μ g/ml insulins, 100 μ g/ml penbritin, when 100IU/ml streptomycin sulfate and multiple distilled water are formed, can be used for treating varicosis, what fester and the diabetes late complication that phlebitis etc. cause caused festers, for reaching better therapeutic effect, can cooperate auxiliary treatment liquid: 5%D-glucose or 5%D-glucose+20%FBS cooperate 20% glycerine water solution+5%FBS (latter can without FBS) to use.
When described recombinant human epidermal growth factor composite biological agent, by 5% hyclone, the 5ng/ml recombinant human epidermal growth factor, the 5%D-glucose, 3 μ g/ml insulins, 100 μ g/ml penbritin, when 100IU/ml streptomycin sulfate and multiple distilled water are formed, can be used for treating wound healing after healthy wound, burn and the operation, for reaching better therapeutic effect, can cooperate auxiliary treatment liquid: 5%D-glucose or 5%D-glucose+20%FBS uses.
When described recombinant human epidermal growth factor composite biological agent, by 5% hyclone, the 5ng/ml recombinant human epidermal growth factor, the 5%D-glucose, when 3 μ g/ml insulins and multiple distilled water are formed, but defying age, beauty treatment; Can cooperate auxiliary liquid for reaching better effect: 20% glycerine water solution+5%FBS uses.
When described recombinant human epidermal growth factor composite biological agent, by the 10ng/ml recombinant human epidermal growth factor, the 5%D-glucose when 2 μ g/ml hydrocortisone and multiple distilled water are formed, can be used for treating gastric ulcer.
Recombinant human epidermal growth factor composite biological agent of the present invention is a main component with recombinant human epidermal growth factor (hrEGF) mainly, add and comprise the essential amino acids of needed by human body and the hyclone of non essential amino acid (FBS), D-glucose (D-glucose), insulin, ampicillin, streptomycin sulfate and hydrocortisone, both provided damage/health tissues to repair required somatomedin, various nutrient substance and promotion cell required when providing simultaneously tissue to repair fast again utilize the composition of these nutrient substance, thereby make because long-term varicosis, phlebitis, the diabetes later stage, the ulcer that lonizing radiation etc. cause or fester can quickly-healing; Make similar skin wounds quickly-healings such as decubital ulcer; Make that burn or accident trauma can quickly-healings; Make gastric ulcer sx even rehabilitation; Make the rapid rehabilitation of damaging ophthalmic diseases; Make that facial skin keeps tender and lovely, wrinkle reduces and mottle is dull even disappearance.Recombinant human epidermal growth factor composite biological agent of the present invention can be used for preparing treatment ulcer, festers, the medicine of wound, burn; Can also be used to produce antidotal cosmetics and cosmetics, make that skin keeps tender and lovely, wrinkle reduces, mottle is dull even disappear, skin is final glossy flexible; Also can be used to prepare the medicine for the treatment of damaging ophthalmic diseases.
The specific embodiment
Below be the volunteer, use the no any exhibit adverse physiological reactions in back for the examination personnel; RhEGF is available from U.S. Sigma company, and article No. is E9644, and amino acid whose content is with hyclone (FBS, interpolation cubage GIBCO).
Embodiment 1, treatment ophthalmic diseases
The prescription 5ng/ml rhEGF+5%D-glucose of preparation+5 μ g/ml insulin+100IU/ml streptomycin sulfates, base soln is multiple distilled water, the degerming of mixing after-filtration, 4 ℃ of cold preservations.
Before the use, need place about 5 minutes eye drip then, each one, every day 3-4 time in room temperature.Particularly use primary effect the best evening just before going to bed.Effect of its treatment ophthalmic diseases is as shown in table 1, and the welder's who is caused by welding before the treatment eyes are burnt and shown as that one's eyes became bloodshot, constant pain, and obstinate uses said preparation after 1 week, and transference cure is also fully recovered and is not had bounce-back.
The effect of table 1. treatment ophthalmic diseases
| The eyes that welding causes are burnt obstinate | The eyes that unknown cause causes are congested and dim-sighted throughout the year | |
| Number | 5 people (male) | 4 people (man: woman=1: 1) |
| Effect | 1 all transference cures and recovery from illness do not have bounce-back | 1-2 week congestive symptom disappears, and the patient feels good |
Embodiment 2, treatment varicosis, phlebitis etc. cause festers and the diabetes late complication causes festers:
Main pharmaceutical formulation: 10%FBS+5ng/ml rhEGF+5%D-glucose+1 μ g/ml hydrocortisone+5 μ g/ml (8 μ g/ml) insulin+100 μ g/ml penbritin+100IU/ml streptomycin sulfates, base soln is multiple distilled water, the degerming of mixing after-filtration, 4 ℃ of cold preservations.
Auxiliary treatment liquid: 5%D-glucose+20%FBS cooperates 20% glycerine water solution, filtration sterilization, 4 ℃ of cold preservations.
At first use 0.9% normal saline to clean wound (severe patient at first uses hydrogen peroxide or 75% alcohol wash), then main preparation is smeared wound, every day sooner or later respectively once.Xerosis cutis or formed the patient of crust also need use auxiliary treatment liquid to smear to keep wound moistening, promotes to absorb and curative effect.When all patients use main preparation, need to use auxiliary treatment liquid smear, increase therapeutic effect, every day 3-4 time in the gap that main preparation uses.Slough face for the mouth that do not fester because the existence of crust has hindered the absorption of preparation effective ingredient, therefore, can adopt hypodermic mode, main preparation is injected directly into activated interstice, once a day.Injected dose is injected in right amount according to the absorbable degree of skin, is generally 0.05ml-0.1ml; Injection is counted and is decided on the size of necrosis area, is generally 1 point/cm
2Said preparation treatment varicosis, phlebitis cause festers, the diabetes late complication causes fester and the effect of decubital ulcer as shown in table 2.
Table 2. treatment varicosis, phlebitis cause festers, the diabetes late complication causes festers and the effect of decubital ulcer
| What varicosis, phlebitis caused festers | What the diabetes late complication caused festers | Decubital ulcer | |
| The treatment number | 6 people | 3 people | 1 people |
| Therapeutic effect | Be the old man in 60-85 year, use main preparation morning, the mouth that festers after 4 hours stops secretion; Mouthful granulation tissue of festering after three days begins growth.2 all left and right sides wound healings, skin recovers the original colour of skin.Insulin is 5 μ g/ml in the main preparation. | Insulin is that festering that cure method, time and effect and treatment varicosis, phlebitis cause is roughly the same the 8 μ g/ml in main preparation. | Cure method, time and effect and treatment varicosis, festering that phlebitis causes is roughly the same. |
Embodiment 3, treat wound healing after healthy wound, burn and the operation
Main pharmaceutical formulation: 5%FBS+5ng/ml recombinant human epidermal growth factor+5%D-glucose+3 μ g/ml insulins+100 μ g/ml penbritin+100IU/ml streptomycin sulfates, solution filtration sterilization, 4 ℃ of cold preservations.
Auxiliary treatment liquid: 5%D-glucose or 5%D-glucose+20%FBS.
At first use 0.9% normal saline to clean wound, then main preparation is smeared wound, every morning, once what wound was bigger or serious can every day twice.In order to make main preparation bring into play better effect, be used auxiliary treatment liquid, to provide regeneration and restoration required enough energy and nutrient substance.Auxiliary treatment liquid uses 3-4 time/day.Treat the effect such as table 3 expression of wound healing after healthy wound, burn and the operation.
The effect of wound healing after table 3. treatment healthy wound, burn and the operation
| Burn, burn and wound | The operation back edge of a knife | |
| Number | 6 people | 3 people |
| Therapeutic effect | The recovery that severe is burnt needs 1.5-3 days; Burn can shift to an earlier date healing in 3-5 days than common treatment; Wound was generally 3-5 days, and cicatrix is slight. | Be generally about 3 days, and cicatrix is slight. |
Embodiment 4, defying age and beauty treatment
Main pharmaceutical formulation: 5%FBS+5ng/ml recombinant human epidermal growth factor+5%D-glucose+3 μ g/ml insulins, filtration sterilization, 4 ℃ of cold preservations.
Auxiliary liquid: 20% glycerine water solution+5%FBS, 4 ℃ of cold preservations.
After cleaning up skin every night, use 0.5ml master's preparation to pat, it is fully absorbed in face.Then, smear an amount of auxiliary liquid, skin is fully preserved moisture.The defying age and the cosmetic result of said preparation are as shown in table 4.
Table 4. defying age and cosmetic result
| Defying age, beauty treatment, speckle dispelling and prevent to be chapped from the cold | |
| Number | 15 people (adult and child) |
| Effect | Use after 14-20 days freckle desalination even disappearance; Skin of face is tender and lovely, and gauffer reduces, and is glossy; The disappearance of being chapped from the cold, skin gloss as before. |
Embodiment 5, treatment gastric ulcer
Pharmaceutical formulation: 10ng/ml recombinant human epidermal growth factor+5%D-glucose+2 μ g/ml hydrocortisone, behind the D/W autoclaving, add other two kinds of compositions when temperature is reduced to room temperature.
Oral 5-10ml/ time on an empty stomach, every day 2-3 time.The effect of said preparation treatment gastric ulcer is as shown in table 5.
The effect of table 5. treatment gastric ulcer
| Gastric ulcer | |
| The treatment number | 5 people |
| Therapeutic effect | Gastroscopy is the result show, a 1-6 month ulcer surface disappears substantially |
Claims (3)
1, a kind ofly treats the recombinant human epidermal growth factor composite biological agent that festers that varicosis, phlebitis or diabetes late complication cause, form by following material: the 2-30ng/ml recombinant human epidermal growth factor, the 2-10%D-glucose, the 10-20% hyclone, 5-10 μ g/ml insulin, 1-5 μ g/ml hydrocortisone, 100 μ g/ml ampicillin and 100IU/ml streptomycin sulfate, solvent are multiple distilled water.
2, composite biological agent according to claim 1, it is characterized in that: described recombinant human epidermal growth factor composite biological agent, by 10% hyclone, the 5ng/ml recombinant human epidermal growth factor, the 5%D-glucose, 1 μ g/ml hydrocortisone, 5 μ g/ml or 8 μ g/ml insulins, 100 μ g/ml penbritin, 100IU/ml streptomycin sulfate and aseptic multiple distilled water are formed.
3, claim 1 or 2 described recombinant human epidermal growth factor composite biological agents in preparation treatment because the application in long-term varicosis, phlebitis, diabetes later stage, ulcer that lonizing radiation cause or the medicine that festers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100006790A CN1330371C (en) | 2004-01-15 | 2004-01-15 | Recombinant human epidermal growth factor compound biological agent and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100006790A CN1330371C (en) | 2004-01-15 | 2004-01-15 | Recombinant human epidermal growth factor compound biological agent and its use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101105551A Division CN101057823B (en) | 2004-01-15 | 2004-01-15 | Composite biological preparation with antisenility and beautifying function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1640491A CN1640491A (en) | 2005-07-20 |
| CN1330371C true CN1330371C (en) | 2007-08-08 |
Family
ID=34866852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100006790A Expired - Fee Related CN1330371C (en) | 2004-01-15 | 2004-01-15 | Recombinant human epidermal growth factor compound biological agent and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1330371C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103055304A (en) * | 2013-01-19 | 2013-04-24 | 卓阳 | Compound temperature-sensitive gel for treating skin ulcer and preparation method thereof |
| CN106727246A (en) * | 2017-02-08 | 2017-05-31 | 上海元茵生物科技有限公司 | Calf serum cell nutrient solution |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191227A (en) * | 1988-10-26 | 1990-07-27 | Otsuka Pharmaceut Factory Inc | Basal solution for hyperalimentation |
| CN1290172A (en) * | 1998-03-07 | 2001-04-04 | 株式会社大熊制药 | Topical composition containing human epidermal growth factor |
| CN1360022A (en) * | 2000-12-19 | 2002-07-24 | 中国科学院上海生物化学研究所 | Recombinant human epidermal growth factor and its preparing process and medicinal composition |
| CN1426813A (en) * | 2001-12-18 | 2003-07-02 | 上海信谊药业有限公司 | Recombination human epidermis growth factor spraying agent and its preparation method |
-
2004
- 2004-01-15 CN CNB2004100006790A patent/CN1330371C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02191227A (en) * | 1988-10-26 | 1990-07-27 | Otsuka Pharmaceut Factory Inc | Basal solution for hyperalimentation |
| CN1290172A (en) * | 1998-03-07 | 2001-04-04 | 株式会社大熊制药 | Topical composition containing human epidermal growth factor |
| CN1360022A (en) * | 2000-12-19 | 2002-07-24 | 中国科学院上海生物化学研究所 | Recombinant human epidermal growth factor and its preparing process and medicinal composition |
| CN1426813A (en) * | 2001-12-18 | 2003-07-02 | 上海信谊药业有限公司 | Recombination human epidermis growth factor spraying agent and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 糖尿病足病变诊断和治疗 许樟荣 等，中国糖尿病杂志，第9卷第3期 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1640491A (en) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Caussa et al. | Epidermal growth factor, innovation and safety | |
| CN106620653A (en) | Composition for treating skin wounds, and preparation method of composition | |
| JP4008192B2 (en) | Skin tissue regeneration promoter comprising ginsenoside Rb1 | |
| CN101152568A (en) | Polypeptide combination preparations having functions of accelerating angiogenesis, organ reactivation and wound healing | |
| TW201338810A (en) | Microcapsule structure having conditioned medium of mesenchymal stem cells and the functions of promoting the regeneration of epidermal cells, angiogenesis and the damage repair for the epidermal cells and method for manufacturing the same | |
| CN101057823B (en) | Composite biological preparation with antisenility and beautifying function | |
| CN107446018A (en) | Promote peptide and its application of wound healing | |
| JP7410574B2 (en) | Skin ointment for labia minora skin treatment | |
| CN1330371C (en) | Recombinant human epidermal growth factor compound biological agent and its use | |
| KR102158969B1 (en) | Composition for treating intractable ulcer comprising substance P | |
| CN111759896A (en) | Pharmaceutical application of total triterpene of pawpaw | |
| CN109731040A (en) | A kind of wound remediation composition, preparation method and applications | |
| US20220168207A1 (en) | Compositions and methods of use for treatment or improvement of the condition and appearance of skin | |
| Matthews-Brzozowska et al. | Revitalization of facial skin based on preparations of patient own blood | |
| CN109223983A (en) | The Chinese medicine composition and pharmaceutical preparation and preparation method and application for treating diabetic foot | |
| KR101162389B1 (en) | Use of organo-silicon compounds for constraining connective damaged tissues | |
| CN108289934A (en) | Plasminogen dosage regimen for wound healing | |
| CN112535690A (en) | Oxygen supply and sterilization integrated ozone eye cleaning and nursing lotion | |
| US20240016893A1 (en) | Compositions and methods for treating wounds | |
| CN113520991B (en) | Nano biological gel for blocking scar formation and reverse repair regulation and preparation method thereof | |
| KR20120058830A (en) | Cosmetic composition for promoting the stemness of adipose-derived stem cell and proliferating skin cell containing hypericum extracts | |
| US20230414663A1 (en) | Composition based on autologous platelet concentrates and a colostrum isolate mixture of biological factors for use in the treatment of conditions requiring tissue repair and regeneration | |
| RU2733392C1 (en) | Combined ophthalmic agent | |
| RU2659959C1 (en) | Composition of the preparation for correction of skin defects | |
| CN106265112B (en) | Promote the drug or cosmetic composition of wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070309 Address after: 100094 State Key Laboratory of agricultural biology, Chinese Agriculture University, 2 West Old Summer Palace Road, Beijing, Haidian District Applicant after: Fang Changge Co-applicant after: Li Ning Co-applicant after: Beijing jipulin Biotechnology Co., Ltd. Address before: 100094 State Key Laboratory of agricultural biology, Chinese Agriculture University, 2 West Old Summer Palace Road, Beijing, Haidian District Applicant before: Fang Changge Co-applicant before: Li Ning |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070808 Termination date: 20140115 |